[{"id":"bda81f7a-e7db-4896-93fc-dd002a685704","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101356","created_at":"2023-10-12T19:12:04.905Z","updated_at":"2024-07-02T16:35:02.238Z","phase":"Phase 1/2","brief_title":"A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma","source_id_and_acronym":"NCT05101356","lead_sponsor":"Tianhong Li","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • MET mutation","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Labvax 3(22)-23 • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2024-05-21"}]